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Alzheimer’s and Parkinson’s disease are the two most common neurodegenerative
disorders. They develop after a progressive death of many neurons in the brain. Although
therapies are available to treat the signs and symptoms of both diseases, the progression
of neuronal death remains relentless, and it has proved difficult to slow or stop. Hence,
there is a need to develop neuroprotective or disease-modifying treatments that stabilize
this degeneration. Red to infrared light therapy (λ =600–1070 nm), and in particular light
in the near infrared (NIr) range, is emerging as a safe and effective therapy that is capable
of arresting neuronal death. Previous studies have used NIr to treat tissue stressed by
hypoxia, toxic insult, genetic mutation andmitochondrial dysfunction with much success.
Here we propose NIr therapy as a neuroprotective or disease-modifying treatment for
Alzheimer’s and Parkinson’s patients.
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INTRODUCTION
Several recent studies in animal models of Alzheimer’s and Parkinson’s disease have reported that
low-level near infrared light (NIr) therapy not only mitigates the behavioral deficits associated with
these conditions but also has neuroprotective effects, slowing the underlying death of neurons.
Current clinical therapies for both diseases do not achieve a comparable slowing of degeneration
and neuroprotection, though they do relieve motor signs in Parkinson’s disease and, to a lesser
extent, the cognitive, and memory deficits in Alzheimer’s disease. In this review, we consider the
evidence for neuroprotection by NIr in animal models of these diseases, the putative mechanisms
by which NIr may work to protect cells against insult, the safety of NIr therapy and finally, the
potential effective use of NIr therapy in patients. First, we provide an overview of Alzheimer’s and
Parkinson’s disease and current treatment options for these conditions.
Abbreviations: AchEIs, acetylcholinesterase inhibitors; ATP, adenosine triphosphate; LED, light emitting diode; MPP+, 1-
methyl-4-phenylpyridinium;MPTP,methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NIr, near infrared light; NMDA, N-methyl-
d-aspartate receptor; SNc, substantia nigra pars compacta; 6OHDA, 6 hydroxydopamine.
Johnstone et al. Shining a Light on Neurodegeneration
OVERVIEW AND CURRENT TREATMENT
OPTIONS FOR ALZHEIMER’S AND
PARKINSON’S DISEASE
Neurodegeneration refers to a progressive death of neurons,
by either genetic environmental or currently unknown factors.
It includes a range of disorders, with the two most common
being Alzheimer’s and Parkinson’s disease. Over time, as more
and more neurons die, the signs and symptoms associated with
each disorder worsen, making many routine day-day activities
increasingly more difficult for patients (Tierney et al., 2013;
Schapira et al., 2014; Brettschneider et al., 2015; Coppedè and
Migliore, 2015; Goedert, 2015; Herrup, 2015; Nelson and Tabet,
2015). In the sections that follow, the different patterns of
neurodegeneration, clinical syndromes and current treatments
for each disease will be considered separately.
Alzheimer’s Disease
Alzheimer’s disease is the name given to an age-related, insidious-
onset, progressive dementia. Individuals suffer progressive
memory and cognitive decline and an overall loss of executive
function (Herrup, 2015; Nelson and Tabet, 2015). There is
an insidious death of neurons across large areas of the brain
(Figure 1); all cortical regions, in particular entorhinal cortex and
hippocampus, together with some subcortical regions, including
the basal nucleus of Meynert, dorsal raphe, and locus coeruleus,
suffer extensive neuronal death (Goedert, 2015; Herrup, 2015).
The disease gained its name after the German neurologist Alois
Alzheimer (1907, 1911) described three features of the end-stage
brain. Two of the three features are proteinopathies (of β-amyloid
and hyperphosphorylated tau); the third is now called gliosis
or inflammation. Many other abnormalities have since been
described in the dementing brain, from small vessel hemorrhage
to oxidative stress (see below).
The Alzheimer’s brain is characterized by a distinct pathology
featuring numerous extracellular β-amyloid plaques and
intracellular neurofibrillary tangles. The β-amyloid peptide,
forming the bulk of the plaques, results from the cleavage
of its precursor, the amyloid precursor protein, while the
neurofibrillary tangles are made up of hyperphosphorylated
tau protein (Braak and Braak, 1995; Hardy and Selkoe, 2002;
Goedert and Spillantini, 2006). Although these pathologies
have a similar overall topography across the brain, being
found in largely the same regions, they tend to have different
patterns of development. The β-amyloid plaques appear first
in the cortex and then later across subcortical regions, while
hyperphosphorylated tau is first observed in the subcortex (e.g.,
locus coeruleus) and then later across the cortex (Brettschneider
et al., 2015).
Debate concerning the cause of this dementia is robust. In
the rare early-onset forms (<65 years), there are strong genetic
links, with mutations of amyloid precursor protein or presenilins
giving rise to an autosomal dominant inheritance pattern of
the disease. The majority of the transgenic animal models of
the disease are, in fact, based on mutations of these proteins
(e.g., Garcia-Alloza et al., 2006; van Eersel et al., 2010). In the
more common late-onset forms (>65 years), genetic associations
are not as strong, with the underlying causes and mechanisms
being unclear (Coppedè and Migliore, 2015; Goedert, 2015;
Herrup, 2015). A number of different hypotheses have been
championed, the most popular of which is the amyloid cascade
hypothesis, which proposes that the accumulation of β-amyloid
in the brain—whether by genetic mutation or other unknown
factors—is the primary driver of pathogenesis, namely the
formation of tangles and subsequent neuronal death (Hardy and
Selkoe, 2002). Inmore recent times, Alzheimer’s pathogenesis has
been proposed to be generated by protein assemblies adopting
alternative conformations and becoming self-propagating, like
prions (Recasens et al., 2014; Brettschneider et al., 2015;
Goedert, 2015). An alternative hypothesis suggests that the
proteinopathies occur downstream from the prime cause, which
is microvascular hemorrhage (Cullen et al., 2005, 2006; Stone,
2008). In this latter view, Alzheimer’s disease is a vasculopathy,
a form of vascular dementia (De la Torre, 2004). In essence, this
hypothesis proposes that the breakdown of cerebral capillaries
as a consequence of aging results in microhemorrhages that in
turn lead to the formation of plaques, tangles, and subsequent
neuronal death (Cullen et al., 2005, 2006; Stone, 2008). We have
argued recently that the dementia is best understood as a pulse-
induced vascular dementia affecting primarily small cerebral
vessels and that the link to age arises from the age-related
hardening of the aorta, which intensifies the destructiveness of
the pulse; that the pathology and symptoms of the disease are
all downstream outcomes of pulse-induced damage to cerebral
vessels (Stone et al., 2015). Finally, there is the hypothesis
that mitochondrial dysfunction is a major contributor to the
neuronal death (Swerdlow and Khan, 2004; Chaturvedi and
Beal, 2008; Gonzalez-Lima et al., 2014; Coppedè and Migliore,
2015). As the organelles responsible for fuelling cell function, if
mitochondria become damaged or dysfunctional, their efficacy
and ATP (adenosine triphosphate) yield would be reduced. This
process would lead to an increase in toxic reactive oxygen species,
generating oxidative stress and subsequent neuronal death, as
observed in Alzheimer’s disease (Swerdlow and Khan, 2004;
Chaturvedi and Beal, 2008; Gonzalez-Lima et al., 2014; Coppedè
andMigliore, 2015). It should be noted that each of these putative
pathogenic processes need not be mutually exclusive, and that all
probably play some role in the disease process (Stone et al., 2015).
The current treatment options for patients with Alzheimer’s
disease are limited. These include acetylcholinesterase inhibitors
(AChEIs) and N-methyl-d-aspartate receptor (NMDA)
antagonists. AChEIs work to slow the rate of cognitive
decline by inhibiting the degradation of acetylcholine, the major
neurotransmitter associated with attention and memory, while
NMDA antagonists work to prevent neurotoxicity in the brain,
in particular in regions that are important for memory formation
and learning. Unfortunately, these drugs are not efficacious
in most patients, may have some toxic side effects and at best
provide only minor palliative symptomatic relief (Nelson and
Tabet, 2015).
Parkinson’s Disease
The clinical syndrome and neuropathology of Parkinson’s disease
are very different to Alzheimer’s disease. Parkinson’s patients
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FIGURE 1 | The major brain sites of pathology in Alzheimer’s and Parkinson’s patients. For Alzheimer’s disease, green shade indicates major regions of cell
loss and β-amyloid plaques and tau pathology, while in Parkinson’s disease, red shade indicates sites of major cell loss and α-synuclein pathology.
have predominately motor signs, including resting tremor,
lead-pipe rigidity, akinesia, and/or bradykinesia (Bergman and
Deuschl, 2002; Jankovic and Poewe, 2012). There may also be
some cognitive impairment but this generally develops very
late in the disease process (Cosgrove et al., 2015). Unlike
Alzheimer’s patients, there are no plaques or tangles and the
zones of neurodegeneration are more limited, at least initially. In
Parkinson’s patients, there is a progressive death of many neurons
in the brainstem, in particular the dopaminergic cells in the
substantia nigra pars compacta (SNc) of the midbrain (Figure 1;
Rinne, 1993; Blandini et al., 2000; Bergman and Deuschl, 2002).
The loss of these cells leads subsequently to a reduction in the
levels of dopamine in the striatum that, in turn, manifests as
the distinct signs of the disease (Blandini et al., 2000; Bergman
and Deuschl, 2002). In addition to this primary loss of brainstem
dopaminergic cells, there are also localized regions of pathology
in the olfactory bulb, dorsal motor nucleus of the vagus nerve and
locus coeruleus (Figure 1) and in much later stages of the disease,
across the cortex (Del Tredici and Braak, 2013; Brettschneider
et al., 2015).
As with Alzheimer’s disease, the factors that cause Parkinson’s
disease and mechanisms of neuronal death are not clear. In
the rarer, early-onset forms of Parkinson’s disease (10–15%),
strong genetic links have been established, with several gene
mutations having been identified (e.g., parkin, PINK1; Corti
and Brice, 2013). There are many transgenic animal models
of the disease, the most relevant involving mutations of the
presynaptic protein, α-synuclein (Blesa et al., 2012; Bezard et al.,
2013). In the more common late-onset of forms of the disease,
the genetic links are much weaker and the causes remain
unknown. As with Alzheimer’s disease, several hypotheses have
been championed. First, the abnormal accumulation α-synuclein
in cells (synucleinopathy)—whether by genetic mutation or other
unknown factors—has been suggested to be the primary factor
driving the neuronal death (Gitler et al., 2009). The abnormal
accumulation of this protein in cells (i.e., Lewy bodies) is thought
to have prion-like propagation (Brettschneider et al., 2015;
Goedert, 2015). Second, there is evidence that Parkinson’s disease
arises after exposure to a neurotoxin, for example paraquat,
rotenone, 6OHDA (6 hydroxydopamine) or MPTP (methyl-4-
phenyl-1,2,3,6-tetrahydropyridine). Indeed, many of the animal
models of the disease are based on exposure to these toxins
(Blesa et al., 2012). Third, there are reports proposing a role for
vascular dysfunction in Parkinson’s pathogenesis. In particular,
it has been suggested that the process of neuronal death begins
after endothelial cell damage and impairment of blood-brain
barrier function (Farkas et al., 2000; Kortekaas et al., 2005; Carvey
et al., 2009; Grammas et al., 2011). Further, the toxins that
induce parkinsonism in animal models, namely 6OHDA and
MPTP, have been shown to generate substantial disruption of the
blood-brain barrier (Carvey et al., 2009). Finally, mitochondrial
dysfunction—caused by either toxic insult, genetic mutation,
vascular damage, or unknown factors—is considered central
in the pathogenesis of Parkinson’s disease (Fukae et al., 2007;
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Exner et al., 2012). This dysfunction leads to a reduction of key
cellular functions and subsequent neuronal death (see above).
Many of these proposed mechanisms of neuronal death—from
mitochondrial dysfunction to vascular compromise and from
abnormal protein assemblies to prion-like propagation—are
similar to those described above for Alzheimer’s disease and are
likely to all contribute to the pathological process, not being
mutually exclusive.
For Parkinson’s patients, there are more treatment options
available than for Alzheimer’s patients. Most Parkinson’s patients
are treated initially with dopamine replacement drug therapy,
which aims to replace the dopamine lost from the system. This
therapy is highly efficacious at reducing motor signs initially, but
with prolonged use, its efficacy tapers and side-effects develop
(e.g., dyskinesias; Bergman and Deuschl, 2002; Jankovic and
Poewe, 2012). At these stages, patients are usually recommended
for surgery with high frequency deep brain stimulation, most
commonly targeting the subthalamic nucleus (Benabid et al.,
2009). This surgery aims to correct the abnormal function of the
basal ganglia circuitry caused by the loss of dopamine and, as
with the drug therapy, is very effective in treating the signs of the
disease. However, for both dopamine drug therapy and surgery,
there is little, if any, evidence for neuroprotection in Parkinson’s
patients (Olanow et al., 2008; Jankovic and Poewe, 2012; Bezard
et al., 2013; Schapira et al., 2014).
In summary, the neuropathology and patterns of
neurodegeneration across the brain in Alzheimer’s and
Parkinson’s disease are very different, hence resulting in very
different signs and symptoms. However, there are similarities
in the proposed mechanisms of neuronal death in each disease.
The current treatments for patients of both diseases offer at best
symptomatic relief (particularly in Parkinson’s disease) but do
not provide neuroprotection or are not disease-modifying, at
least in humans.
FROM THE BENCH TO THE CLINIC: THE
EVIDENCE FOR NEUROPROTECTION BY
NEAR INFRARED LIGHT (NIr) TREATMENT
IN ALZHEIMER’S AND PARKINSON’S
DISEASE
Low-level laser or LED (light emitting diode) therapy using
red to infrared light (λ = 600–1070 nm), conflated here to
the term “near infrared light” (NIr), is an emerging, putative
neuroprotective treatment that is showing promise in several pre-
clinical models of disease. For example, NIr has been reported
beneficial in animal models of retinal disease (Eells et al.,
2004; Natoli et al., 2010, 2013; Albarracin et al., 2013; Begum
et al., 2013; Gkotsi et al., 2014), traumatic brain (Ando et al.,
2011; Oron et al., 2012; Quirk et al., 2012a; Xuan et al., 2013,
2014, 2015) and optic nerve (Fitzgerald et al., 2010) injury,
experimentally-induced stroke (Lapchak et al., 2004; DeTaboada
et al., 2006; Oron et al., 2006), familial amyotrophic lateral
sclerosis (Moges et al., 2009), multiple sclerosis (Muili et al.,
2012), Parkinson’s disease (Liang et al., 2008; Whelan et al.,
2008; Ying et al., 2008; Shaw et al., 2010; Peoples et al., 2012;
Moro et al., 2013, 2014; Purushothuman et al., 2013; Vos et al.,
2013; Johnstone et al., 2014a,b; Darlot et al., 2015; El Massri
et al., 2015; Reinhart et al., 2015a,b) and Alzheimer’s disease
(Michalikova et al., 2008; DeTaboada et al., 2011; Grillo et al.,
2013; Purushothuman et al., 2014, 2015). In humans, NIr therapy
has been reported to improve executive, cognitive, and emotional
functions (Barrett and Gonzalez-Lima, 2013; Blanco et al., 2015),
together with performance in a range of clinical tests after
ischaemic stroke (Lampl et al., 2007; Lapchak, 2010), brain
trauma (Naeser et al., 2011, 2014), depression (Schiffer et al.,
2009) and in age-related macular degeneration (Merry et al.,
2012). The fact that NIr therapy has been reported to be effective
in so many different models of disease and in a range of neural
systems suggests that it is not a targeted therapy, but instead,
acts to mitigate ubiquitous processes relating to cell damage and
death. Recent work indicates that NIr is effective in reducing
neuronal death induced by apoptosis, but not necrosis (Quirk
et al., 2012a). The pathway to apoptosis is likely to involve a
critical decline in cellular energy production (Galluzzi et al.,
2012), that NIr may help to restore (Hamblin and Demidova,
2006; Liang et al., 2008; Ying et al., 2008; Desmet et al., 2009; Rojas
and Gonzalez-Lima, 2011; Chung et al., 2012; Begum et al., 2013;
Gkotsi et al., 2014). This mechanism is presumably common
to all the above mentioned conditions and is perhaps why NIr
therapy has such broad potential applications. In the context of
Alzheimer’s and Parkinson’s disease, although they have distinct
initiating causes, both diseases converge on common pathways
of inflammation and oxidative stress, mitochondrial dysfunction
and neuronal death, indicating that NIr may be beneficial to both
through the same protective mechanisms.
NIr for Alzheimer’s Disease
The majority of the studies reporting beneficial effects of NIr
treatment in Alzheimer’s disease or dementia have been in
transgenic animal models, in particular those displaying β-
amyloid (APP/PS1: DeTaboada et al., 2011; Purushothuman
et al., 2014, 2015; TASTPM; Grillo et al., 2013; CD1: Michalikova
et al., 2008), or tau (K369I: Purushothuman et al., 2014, 2015)
pathologies (Table 1). In general, with either acute (weeks;
Michalikova et al., 2008) or more chronic (months; DeTaboada
et al., 2011; Grillo et al., 2013; Purushothuman et al., 2014,
2015) NIr treatment, these studies have reported reductions in β-
amyloid plaques, neurofibrillary tangles of hyperphosphorylated
tau protein, inflammation and oxidative stress, together with
increased ATP levels and improved overall mitochondrial
function. In addition, NIr reduced the characteristic cognitive
deficits associated with the CD1 (Michalikova et al., 2008) and
APP/PS1 (DeTaboada et al., 2011) transgenic mouse models. One
in vitro study reported that, after internalization of β-amyloid
into human neuroblastoma cells, NIr treatment increased ATP
levels and overall cell number, while reducing β-amyloid
aggregates (Sommer et al., 2012).
To the best of our knowledge, there have been no major
publications—at least in peer-reviewed journals—on the efficacy
of NIr in Alzheimer’s patients. There are some web pages
referring to either an Alzheimer extracranial “helmet,” housing
many LEDs of wavelengths ranging from 660 to 1070 nm (e.g.,
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TABLE 1 | Studies reporting on NIr treatment in Alzheimer’s disease.
Findings with NIr application Study Model Species
↑ Cell survival Sommer et al., 2012 In vitro (neuroblastoma cells internalized with β-amyloid) Human cells
↑ ATP content
↓ β-amyloid aggregates
↓ β-amyloid plaques Purushothuman et al., 2014, 2015 APP/PS1, K3691 transgenics (chronic) Mouse
↓ Oxidative stress
↓ hyperphosphorylated tau




↓ β-amyloid plaques Grillo et al., 2013 TASTPM transgenic (chronic) Mouse
↓ Oxidative stress
↓ Hyperphosphorylated tau
↑ Heat shock proteins
↑ Cognitive behavioral deficits Michalikova et al., 2008 CD1 transgenic (acute) Mouse





an intranasal device delivering NIr to the brain (http://www.
mediclights.com/wp-content/uploads/2013/11/Alzheimer-with-
intranasal-light-08-22-13-1.pdf). However, there are no reports,
either published, or in progress, of clinical trials on Alzheimer’s
patients. Two clinical studies by Naeser et al. (2011, 2014) have
reported improvements in executive function, learning and
memory after NIr treatment—delivered via an extracranial
helmet-like device using two LEDs—in a small number of
patients suffering chronic traumatic brain injury. Further, there
are two human studies in healthy individuals reporting that NIr
therapy improves attention and short-term memory (Barrett and
Gonzalez-Lima, 2013) and executive functions (Blanco et al.,
2015). Although these studies are promising in the sense that NIr
therapy resulted in cognitive improvements, the subjects were
not Alzheimer’s patients.
NIr for Parkinson’s Disease
Mainly due to the existence of effective toxin-based in vitro and
in vivomodels, there have been considerably more reports on the
beneficial effects of NIr for Parkinson’s disease (Table 2). The first
studies to report neuroprotection byNIr after parkinsonian insult
demonstrated that NIr treatment reduced cell death, increased
ATP content and decreased levels of oxidative stress in rat
striatal and cortical cells exposed to the parkinsonian toxins
rotenone and MPP+ (1-methyl-4-phenylpyridium) in vitro
(Liang et al., 2008; Ying et al., 2008). In cultures of human
neuroblastoma cells engineered to overexpress α-synuclein,
NIr increased mitochondrial function and reduced oxidative
stress after MPP+ (1-methyl-4-phenylpyridinium) exposure
(Trimmer et al., 2009; Quirk et al., 2012b). Further, in hybrid
cells bearing mitochondrial DNA from Parkinson’s patients,
mitochondrial movement along axons improved substantially
after NIr treatment, with movement restored to near control
levels (Trimmer et al., 2009).
There have also been many in vivo studies of NIr-induced
neuroprotection in various animal models of Parkinson’s disease
(Table 2). In MPTP-treated mice (Shaw et al., 2010; Peoples
et al., 2012; Moro et al., 2013, 2014; Johnstone et al., 2014b;
El Massri et al., 2015; Reinhart et al., 2015b) and 6OHDA-
lesioned rats (Reinhart et al., 2015a), NIr treatment saved many
dopaminergic cells from death. Further, results were similar
whether the therapy was applied before, at the same time
or well after the insult, indicating that NIr both conditions
healthy neurons to resist a subsequent insult and rescues
damaged neurons following an insult (Peoples et al., 2012).
The rescue of neurons is particularly relevant to the clinical
reality of the parkinsonian condition, in which individuals have,
at presentation, already suffered significant degeneration, so
that treatment follows neuronal loss. In the K369I transgenic
mouse model of frontotemporal dementia, which also shows
parkinsonian signs and a chronic and progressive degeneration
of dopaminergic cells in the SNc, NIr treatment decreased
oxidative stress and hyperphosphorylated tau and increased
dopaminergic cell survival in the SNc (Purushothuman et al.,
2013). Recently, NIr therapy has been used in a non-human
primate MPTP model of Parkinson’s disease with very promising
results. All of the NIr-treated MPTP monkeys had a greater
number of surviving dopaminergic nigral cells and striatal
terminations compared to those that were not treated (Darlot
et al., 2015).
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Together with preserving dopaminergic cell survival, NIr has
been shown to correct abnormal neuronal activity generated
by the parkinsonian condition (Shaw et al., 2012). Using
Fos immunohistochemistry (a well-established measure of cell
activity), the overactivity of neuronal firing in the subthalamic
region, characteristic of parkinsonian cases, was reduced
substantially after NIr therapy. This reduction did not quite reach
control levels, indicating that the restoration was partial, and
was attributed to the functional repair of damaged dopaminergic
cells in the SNc, allowing these cells to resume producing and
releasing dopamine at their terminals in the striatum (Shaw
et al., 2012). This functional restoration may well-underlie the
improved motor behavior observed after NIr treatment (see
below).
A number of previous studies have reported clear
improvements inmotor behavior in animalmodels of Parkinson’s
disease following NIr treatment. In MPTP-treated mice, NIr
therapy improved various parameters of locomotion, for example
mobility, and velocity (Whelan et al., 2008; Moro et al., 2013;
Reinhart et al., 2015b). NIr treatment also delayed disease
TABLE 2 | Studies reporting on NIr treatment in Parkinson’s disease.
Findings with NIr application Study Model Species
↑ Cell survival (striatal and cortical cells) Liang et al., 2008; Ying et al., 2008 In vitro (rotenone, MPTP) Rat cells
↑ ATP content
↓ Oxidative stress




↑ mitochondrial movement Trimmer et al., 2009 In vitro (hybrid cells with mitochondrial
DNA from Parkinson’s disease
patients)
Human cells
↑ Cell survival (TH+ cells) Shaw et al., 2010 MPTP (acute) Mouse
↑ Cell survival (TH+ cells) Peoples et al., 2012 MPTP (chronic)
↑ Cell survival (TH+ cells) Purushothuman et al., 2013 K369I transgenic (chronic)
↑ Cell survival (TH+ cells) Moro et al., 2013, 2014; Johnstone
et al., 2014b
MPTP (acute)
↑ Cell survival (TH+ cells) El Massri et al., 2015 MPTP (acute, sub-chronic)
↑ Cell survival (TH+ cells) Reinhart et al., 2015b MPTP (acute)
↑ Cell survival (TH+ cells) Reinhart et al., 2015a 6OHDA hemi-parkinsonian Rat
↑ Cell survival (TH+ and Nissl-stained cells) Darlot et al., 2015 MPTP (sub-acute) Monkey
↓ Oxidative stress Purushothuman et al., 2013 K369I transgenic (chronic) Mouse
↓ Hyperphosphorylated tau
↑ Flight Vos et al., 2013 pink1 mutant Flies
↑ Complex IV-dependent respiration
↓ Mutant mitochondria defects
↓ Abnormal basal ganglia activity Shaw et al., 2012 MPTP (acute) Mouse
(Fos immunoreactivity)
↑ Locomotive behavior Whelan et al., 2008 MPTP (acute) Mouse
Desmet et al., 2009 MPTP (acute)
Quirk et al., 2012b A53T(<-synuclein transgenic)
Moro et al., 2013; Reinhart et al.,
2015b
MPTP (acute)
↓ Apomorphine-induced rotations Reinhart et al., 2015a 6OHDA hemi-parkinsonian Rat
↑ Locomotive behavior, clinical signs Darlot et al., 2015 MPTP (sub-acute) Monkey
↓ Clinical signs Zhao et al., 2003; Maloney et al.,
2010; Burchman, 2011
Parkinson’s patients Human
Quietmind Foundation trial (http://
www.youtube.com/watch?v=9X-
hjgay7pg)
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progression and reduced the severity of the disease phenotype
in transgenic mice expressing the A53T human α-synuclein
mutation (Quirk et al., 2012b). Further, NIr treatment reduced
apomorphine-induced rotational behavior in a 6OHDA-lesioned
hemiparkinsonian rat model (Reinhart et al., 2015a). There
is also evidence that NIr treatment rescues flight and mutant
mitochondria defects, together with promoting complex
IV-dependent respiration, in pink1 mutant flies (Vos et al.,
2013). Perhaps the strongest evidence for improved behavioral
outcomes after NIr treatment has been in the MPTP-treated
monkey model of the disease. The NIr-treated MPTP monkeys
all had reduced clinical signs compared to untreated MPTP
monkeys; these reductions in clinical signs were still evident well
after the period of NIr treatment, in fact up to 3 weeks after in
many of the cases. This indicates that the therapeutic effects of
NIr are long-lasting and not confined to periods when NIr is
being applied (Darlot et al., 2015).
As with Alzheimer’s disease, there have been few reports to
date on the efficacy of NIr treatment in Parkinson’s disease
patients (Table 2). From the Quietmind Foundation trial, there
is a linked YouTube video (http://www.youtube.com/watch?
v=9X-hjgay7pg) of a Parkinson’s patient displaying improved
movement and reduced tremor after extracranial application
of NIr, but few details are provided. There is a recent
non-controlled and non-randomized clinical report indicating
improved speech, cognition, freezing episodes and gait after
extracranial NIr therapy in parkinsonian patients (Maloney
et al., 2010); there are also some clinical reports suggesting
improvements in parkinsonian signs in the majority of patients
after NIr application through an intranasal device (Zhao et al.,
2003). Finally, there is a serendipitous finding in one Parkinson’s
patient that was treated with NIr for a dental problem. This
patient was reported to display a reduction in his parkinsonian
signs following NIr treatment to the posterior regions of the
cranium/upper neck (Burchman, 2011).
In summary, a number of experimental studies have
demonstrated that NIr therapy improves motor behavior and
provides neuroprotection in various rodent models of both
Alzheimer’s and Parkinson’s disease; for Parkinson’s disease, these
benefits have been reported in a non-human primate model as
well. However, the evidence for therapeutic benefit at the clinical
level is far sparser, prompting the need for systematic, large-
scale clinical trials of NIr therapy in Alzheimer’s and Parkinson’s
patients.
HOW DOES NIr WORK TO
NEUROPROTECT?
The mechanisms that underpin NIr-induced neuroprotection
are not entirely clear, although they appear to operate in at
least two different biological levels. First, NIr acts at a cellular
level, activating intracellular cascades that ultimately contribute
to the survival of the target, and possibly neighboring, cells
and/or stimulating neurogenesis. Second, NIr appears capable
of triggering systemic protective mechanisms; this presumably
involves as yet unidentified circulating cellular or humoral
factors that can transduce protective effects to the brain
(Figure 2).
Direct Stimulation of Cells
There is a large body of work reporting that a number of
molecular and cellular systems are influenced byNIr. At a cellular
level, NIr displays a biphasic dose-response curve, suggesting
that NIr is a low-level stressor of cells and that the activation of
endogenous cellular stress response systems is likely to be central
to its efficacy (Hamblin and Demidova, 2006; Desmet et al., 2009;
Rojas and Gonzalez-Lima, 2011; Chung et al., 2012). The main
direct target of NIr appears to be cytochrome c oxidase, a key
enzyme of the mitochondrial respiratory chain (Figure 2A). This
enzyme is a photoacceptor of light in the NIr range; NIr exposure
produces a redox change in cytochrome c oxidase which causes
a transient change in mitochondrial membrane potential, leading
to increase ATP production and a burst in low levels of reactive
oxygen species (Hamblin and Demidova, 2006; Desmet et al.,
2009; Rojas and Gonzalez-Lima, 2011; Chung et al., 2012). This,
in turns, triggers a cascade of secondary downstream signaling
pathways that collectively stimulate endogenous cell protection
and repair mechanisms (Hamblin and Demidova, 2006; Desmet
et al., 2009; Chung et al., 2012; Rojas and Gonzalez-Lima,
2011). This modulation of multiple molecular systems appears
capable of both conditioning neurons to resist future damage
and accelerating repair of neurons damaged by a previous or
continuing insult (e.g., Liang et al., 2008; Ying et al., 2008).
In addition to protecting and repairing damaged or
dysfunctional neurons, there is emerging evidence from
mouse models of traumatic brain injury that NIr also stimulates
neurogenesis and synaptogenesis (Figure 2A). In a series of
studies using a mouse model of traumatic brain injury, Xuan
and colleagues found that a NIr treatment regime that improved
neurological performance (Xuan et al., 2013), also increased
markers of neuroprogenitor proliferation in the hippocampal
region (i.e., dentate gyrus) and subventricular zone (Xuan
et al., 2014), brain regions known to harbor neural stems cells.
Other early responses in these regions included up-regulation
of brain-derived neurotrophic factor, which was associated
with subsequent up-regulation of synaptogenesis markers in
the lesion site (Xuan et al., 2013). Similar observations of
NIr-induced increases in neuroprogenitor cell proliferation in
the subventricular zone have been made in a rat model of stroke
(Oron et al., 2006).
It should be noted that these studies have focussed on the effect
of NIr on neurons; similar NIr-induced cellular mechanisms
may also be at play within brain capillary endothelial cells
(Figure 2A). Mitochondrial dysfunction of these cells has been
related to various vascular conditions, including atherosclerosis
and hypertension (Tang et al., 2014). In the context of
neurodegeneration, both Alzheimer’s and Parkinson’s disease
have been implicated as vascular disorders, with suggestions that
the neurodegenerative process begins with the breakdown of the
integrity of small cerebral vessels and the blood-brain barrier
(see above). This “breakdown” may begin with mitochondrial
dysfunction (Grammas et al., 2011). Following, we propose that
NIr-induced neuroprotection in Alzheimer’s and Parkinson’s
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disease might involve repair of the damaged mitochondria in
local endothelial cells, leading subsequently to a restoration of
the integrity of the endothelial network and blood-brain barrier
in the region, resulting ultimately in improved neuronal survival
(Figure 2A).
Indirect Stimulation of Systemic Factors
In addition to direct beneficial actions on damaged cells, there
is increasing evidence that NIr treatment might also activate
a more global, systemic response (Figure 2B). This evidence
arises from the observation that local application of NIr to a
particular body part can induce beneficial effects in distant body
tissues (Braverman et al., 1989; Stone et al., 2013; Johnstone
et al., 2014a,b, 2015). For example, neuroprotection of the mouse
brain against MPTP insult has been demonstrated following
the “remote” application of NIr to the dorsum of the animal,
with no direct application to the head (Stone et al., 2013;
Johnstone et al., 2014a,b, 2015). While the mechanism remains
unknown, it presumably involves the stimulation of one or
more circulating molecules or cell types. One possibility is
the stimulation of immune cells, for example mast cells and
macrophages, that could help neuroprotect cells in the brain
(Byrnes et al., 2005; Chung et al., 2012; Muili et al., 2012).
There may also be effects on inflammatory mediators, as NIr is
associated with down-regulation of pro-inflammatory cytokines
and up-regulation of anti-inflammatory cytokines (Muili et al.,
2012). In addition, bone marrow-derived stem cells may also be
involved; a series of studies has demonstrated that NIr exposure
increases proliferation of c-kit-positive cells in the bone marrow
and that, following myocardial infarction in rats, these cells
are mobilized and recruited specifically to the site of damage
where they are associated with a reduction in myocardial infarct
size and ventricular dilatation (Tuby et al., 2011). These cells,
together with immune cells, may release trophic factors (e.g.,
nerve growth factor, brain-derived neurotrophic factor) that
improve the function of dying cells and help their survival (Hou
et al., 2008).
Another possibility is for a signaling system between
mitochondria in different body tissues. Mitochondria in
distress in one body tissue have been suggested to produce
an unidentified extracellular signal (mitokine) that is then
transmitted to cells in remote body tissues and as a consequence
induces a mitochondrial stress response (Durieux et al., 2011;
Taylor et al., 2014). In relation to NIr and Alzheimer’s and
Parkinson’s disease, NIr applied to remote tissue may prompt
a signal system between mitochondria of peripheral tissues
and brain, inducing repair mechanisms in the damaged cells
in the brain (Johnstone et al., 2014a,b, 2015). Taken all
together, the systemic mechanisms underlying remote NIr-
induced neuroprotection may share similarities with other
remote tissue protection phenomena—these include remote
ischaemic conditioning, where induction of brief ischaemic
episodes in one organ provides protection of other distant
organs (Hausenloy and Yellon, 2008; Yetgin et al., 2012), and
the so-called “abscopal” effect sometimes observed in radiation
treatment of metastatic cancer, where treatment targeted at a
tumor leads to not only a shrinking of the local tumor but also
a shrinking of tumors far from the treated area (Postow et al.,
2012).
More research is required to understand the interplay between
direct cellular and indirect systemic mechanisms of NIr-induced
protection. Both appear capable of acting independently—the
findings of numerous in vitro cell culture studies reporting
that NIr is neuroprotective, indicate clearly that the indirect
systemic effect is not necessary for NIr-induced neuroprotection
and repair of damaged neurons (Hamblin and Demidova, 2006;
Desmet et al., 2009; Rojas and Gonzalez-Lima, 2011; Chung
et al., 2012), while accumulating evidence from mouse models
suggest remote NIr application provides neuroprotection in the
absence of direct NIr stimulation (Johnstone et al., 2014b, 2015;
Farfara et al., 2015). The phenomenon of indirect NIr-induced
neuroprotection is likely to involve the same mechanisms,
at a cellular level, as those that provide neuroprotection to
damaged cells with direct NIr stimulation (i.e., stimulation
of mitochondrial function; Figure 2A). Although the concept
of indirect, remote NIr therapy holds promise for future
applications, it is not yet as fully understood and developed
as direct NIr therapy, thus our subsequent discussion will
focus primarily on direct NIr stimulation. Further, some early
results in an animal model of Parkinson’s disease suggest that,
although remote NIr provides neuroprotection, this protection
was not as robust as when NIr was applied directly to the
head (Stone et al., 2013; Johnstone et al., 2014b; presumably
stimulating local neurons and/or endothelial cells). In other
words, neuroprotection was achieved with both local and remote
NIr treatment, but the local treatment was the more effective.
As a working hypothesis, we suggest that direct stimulation
of the mitochondria and reparative mechanisms, either in the
neurons themselves or in the local endothelial cells (and/or
stimulation of neurogenesis), forms the primary mechanism
of NIr-induced neuroprotection. A more systemic (indirect)
stimulation of immune and/or stem cells may form a secondary
and complementary mechanism. We suggest that stimulation of
both direct and indirect mechanisms would generate maximum
NIr-induced neuroprotection.
IS NIr THERAPY SAFE?
To date, there are no reports of major safety issues nor side-effects
after NIr treatment. The commercial LED panels for NIr therapy
have already received non-significant risk status by the Food
and Drug Administration and previous studies have indicated
no adverse impact on brain tissue structure and function after
NIr treatment (power range from ∼1 to 700mW/cm2; Desmet
et al., 2006; Hamblin and Demidova, 2006; Ilic et al., 2006; Zivin
et al., 2009; McCarthy et al., 2010; Naeser et al., 2011, 2014; Rojas
and Gonzalez-Lima, 2011; Chung et al., 2012; Tata andWaynant,
2012; Quirk et al., 2012a,b; Moro et al., 2014). There is one
sole account of some neuronal damage and negative behavioral
outcomes inmice, but this was evident after an exceptionally high
power intensity (750mW/cm2; Ilic et al., 2006), approximately
one hundred times higher than the dose required to elicit a
therapeutic response (e.g., <10mW/cm2). Hence, when taken
together, these data indicate that when NIr was applied at
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FIGURE 2 | The putative NIr protective mechanisms in the brain. (A) Direct NIr stimulation of the mitochondria of the damaged neurons or endothelial cells. This
stimulation would repair the damage leading to neuronal protection. NIr may also stimulate neurogenesis in the hippocampus and/or synaptogenesis in the damaged
neurons (B) indirect (remote) stimulation via circulating immune cells and/or bone marrow stem cells leading to neuronal protection. The latter is similar to the so-called
“abscopal” effect in the treatment of cancer metastasis. We suggest that the primary mechanism is the direct effect, of neurons and/or of endothelial cells, while the
systemic indirect effect forms a secondary supportive mechanism.
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therapeutic doses (and even well above these doses), its impact
on body tissue was overwhelmingly positive, and had a very large
safety margin of application (Desmet et al., 2006; Hamblin and
Demidova, 2006; Ilic et al., 2006; Zivin et al., 2009; McCarthy
et al., 2010; Naeser et al., 2011, 2014; Rojas and Gonzalez-Lima,
2011; Chung et al., 2012; Tata and Waynant, 2012; Quirk et al.,
2012a,b; Moro et al., 2014). Further, there appears to be no
longer-term side effects associated with NIr application; in a
long-term study in rats, no adverse effects were noted after daily
treatment for 12 months (McCarthy et al., 2010).
NIr THERAPY IN ALZHEIMER’S AND
PARKINSON’S DISEASE PATIENTS: CAN IT
WORK?
The key question that still remains is whether NIr therapy can
be neuroprotective in humans. In order for maximum effect,
the primary goal would be for sufficient NIr signal to reach the
main zones of pathology, to elicit a protective, or reparative
effect within damaged cells (and perhaps also neurogenesis);
a secondary goal would be for the NIr signal to also trigger
systemic neuroprotective factors, for example circulating cells or
molecules (see above).
The issue of NIr reaching the zones of pathology is of most
concern in humans. There are no such concerns when there are
few or no tissue barriers, as in the culture dish (Eells et al., 2004;
Wong-Riley et al., 2005; Liang et al., 2008; Ying et al., 2008), the
retina (Natoli et al., 2010, 2013; Albarracin et al., 2013; Begum
et al., 2013) or in the mouse brain (Shaw et al., 2010; Peoples
et al., 2012; Moro et al., 2013; Purushothuman et al., 2013, 2014,
2015; Johnstone et al., 2014b; El Massri et al., 2015; Reinhart et al.,
2015b). But can NIr be effective when there are many intervening
body tissues, namely skin, thick cranium, and meninges, and
brain parenchyma, as in humans?
Previous studies have estimated that NIr can be measured—
through body tissues—at a distance of 20–30mm from the
transmission source (Lapchak et al., 2004; Byrnes et al., 2005;
Zivin et al., 2009), albeit with a considerable dissipation of signal
(DeTaboada et al., 2006; Zivin et al., 2009; Shaw et al., 2010;
Abdo et al., 2013; Moro et al., 2014). For example, Moro et al.
(2014) have noted that at a distance of 10mm through brain
parenchyma, the NIr signal is <1% of that emitted from the
source. They estimated a 65% reduction of signal across each
millimeter of brain tissue.
For Alzheimer’s patients, the NIr signal—when applied from
an extracranial source—should be able to reach the main zones
of pathology located in the cortex, 8–10mm below the cranium,
and have therapeutic effects (Figure 3). Indeed, there have been
several human studies reporting that NIr therapy is beneficial
when the target region is in the cortex, for example in patients
suffering trauma (Naeser et al., 2011, 2014), stroke (Lampl et al.,
2007; Lapchak, 2010) or depression (Schiffer et al., 2009). Further,
NIr therapy has been shown to improve higher-order cortical
functions in healthy individuals, such as sustained attention
and short-term memory (Barrett and Gonzalez-Lima, 2013),
together with executive functions (Blanco et al., 2015). Hence,
in Alzheimer’s disease, NIr-induced neuroprotection appears
feasible because the main zones of pathology are in superficial
structures seemingly within reach from an extracranial source.
For Parkinson’s patients, the distance from cranium to the
main zone of pathology in the brainstem is much greater,
being 80–100mm (Johnstone et al., 2014a). Hence, it is unlikely
that NIr signal from an extracranial source would reach the
target cells (Figure 3); at these distances, the signal would be at
best extremely weak and probably undetectable. This presents
a clear limitation in the use of extracranially-applied NIr as
a neuroprotective treatment in Parkinson’s patients. For these
reasons, we have developed a novel method of delivering effective
NIr signal to deeper brainstem structures, using an intracranial
optical fiber device. This device, when implanted within the
brain parenchyma near the region of pathology, delivers NIr
in effective doses for neuroprotection, for improved behavioral
outcomes and with no toxicity to surrounding tissues in both
rodents (Moro et al., 2014; Reinhart et al., 2015a) and non-human
primates (Darlot et al., 2015).
We should note that in Parkinson’s patients, although
extracranially-delivered NIr may not reach the zones of
pathology in the brainstem and hence, we argue, have
limited neuroprotection, it may nevertheless provide some
purely symptomatic effects. In Parkinson’s disease, there is
much abnormal activity in the cortex (Samuel et al., 1997;
Sabatini et al., 2000; Haslinger et al., 2001), a structure
that is within range of NIr signal when applied from an
extracranial source (see above). NIr may help normalize
this neural activity, leading to improvements in movement
(Johnstone et al., 2014a). Here, the NIr therapy would impact
on the abnormal neural circuitry that has resulted from
the loss of dopaminergic cells, rather than on the diseased
dopaminergic cells themselves. This form of NIr treatment
would be purely symptomatic, rather than neuroprotective.
We propose that such symptomatic treatment by NIr, namely
clinical improvements without any underlying changes to
the pathology, would be short-term; for long-lasting clinical
improvements, we suggest that a reduction in the pathology
through neuroprotection would be required. Hence, for
neuroprotective and maximum therapeutic effects in Parkinson’s
disease, NIr would need to be applied via the intracranial optical
fiber device (Figure 3).
In summary, there are clear indications that NIr can be an
effective neuroprotective treatment for both neurodegenerative
diseases, although the modes of delivery would be different; while
extracranial NIr therapy would suffice for Alzheimer’s disease,
intracranial NIr therapy would be required for Parkinson’s
disease (Figure 3).
WHAT WOULD BE THE ADVANTAGES OF
USING NIr THERAPY?
There would be several key advantages for the use of NIr
therapy over current treatments for both Alzheimer’s and
Parkinson’s disease. First and foremost, NIr has the potential
to be neuroprotective. A growing body of pre-clinical evidence
indicates that NIr therapy slows or stops disease pathology (Liang
et al., 2008; Ying et al., 2008; Shaw et al., 2010; Peoples et al.,
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FIGURE 3 | Potential NIr applications in Alzheimer’s and Parkinson’s patients. For effective neuroprotection, NIr could be applied extracranially in Alzheimer’s
disease (e.g., in the form of a helmet) and intracranially in Parkinson’s disease (e.g., in the form of an optical fiber linked to a LED or laser source). NIr would be
delivered very close to the diseased cells in the neocortex (for Alzheimer’s) and brainstem SNc (for Parkinson’s). In Parkinson’s patients selected for deep brain
stimulation, the NIr optical fiber could be implanted surgically at the same time, for neuroprotection of remaining dopaminergic cells (see text for details).
2012; Moro et al., 2013; Purushothuman et al., 2013, 2014,
2015; Johnstone et al., 2014b; El Massri et al., 2015; Reinhart
et al., 2015a,b). This is something that the current mainstay
of treatments for both diseases—drug therapy—does not do.
Second, it is safe, with no reported side effects (see above). Third,
treatment would be simple. For potential neuroprotection in
Alzheimer’s disease, patients would apply the NIr extracranially,
perhaps in the form of a helmet or a hand held device, over the
entire cranium; in Parkinson’s disease, patients would require
a minimally invasive surgical stereotactic procedure for the
insertion of a NIr optical device within the brain; in some
cases, this procedure might be undertaken at the same time as
stereotactic surgery for deep brain stimulation (see below). This
device would be linked to a battery source and pacemaker device
(as with patients receiving deep brain stimulation; Benabid et al.,
2009) applying the NIr to the brainstem when required. The
procedural risks would be comparable to those of single electrode
deep brain stimulation.
CONCLUSIONS AND IMPLICATIONS OF
FUTURE THERAPY
Although in its infancy, with the bulk of results still at the
pre-clinical “proof of concept” stage, NIr therapy has the
potential to develop into a safe and effective neuroprotective
treatment for patients with Alzheimer’s and Parkinson’s disease
(and presumably other neurodegenerative diseases such multiple
sclerosis and amyotrophic lateral sclerosis). If NIr was applied
at early stages of the disease process, for example at first
diagnosis, it could potentially slow further progression by
protecting neurons from death. Consequently, over time, the
greater neuronal survival would lessen the clinical signs and
symptoms. Further, NIr therapy—because of its lack of side-
effects and neuroprotective potential—is amenable to use in
conjunction with other treatments. For example, patients may
have NIr therapy with a reduced dosage of drugs as a first
line treatment; the potential neuroprotective effect of NIr could
prolong the efficacy of the drug therapy. Further, in Parkinson’s
patients selected for deep brain stimulation, they may also have
an NIr optical fiber implanted surgically at the same time,
thereby potentially offering neuroprotection of the remaining
dopaminergic cells. There is much to do in further developing
this treatment, but the therapeutic possibilities are many and
the potential outcomes very exciting. We await the outcomes
of major clinical trials using NIr therapy on these patients with
much anticipation.
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